Structure of Dovitinib
CAS No.: 405169-16-6
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Dovitinib is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM.
Synonyms: CHIR-258; TKI258
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 405169-16-6 |
Formula : | C21H21FN6O |
M.W : | 392.43 |
SMILES Code : | CN1CCN(CC1)C2=CC3=C(N=C(N3)C4=C(C5=C(NC4=O)C=CC=C5F)N)C=C2 |
Synonyms : |
CHIR-258; TKI258
|
MDL No. : | MFCD10565680 |
InChI Key : | PIQCTGMSNWUMAF-UHFFFAOYSA-N |
Pubchem ID : | 135398510 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Target |
|
In Vitro:
Concentration | Treated Time | Description | References |
YTN16 cells | 1.0μM | Dovitinib significantly inhibited phosphorylation of FGFR1 and PDGFRB in YTN16 cells, and repressed the expression of EMT markers Vimentin, SNAI1, SNAI2, and ZEB1, while inducing E-cadherin expression. | PMC10592091 | |
HGC-27 cells | 1.0μM | Dovitinib significantly inhibited phosphorylation of FGFR1 and PDGFRB in HGC-27 cells, and repressed the expression of EMT markers Vimentin, SNAI1, SNAI2, and ZEB1, while inducing E-cadherin expression. | PMC10592091 | |
HCT-116 | 3.05 μM | 72 hours | To evaluate the inhibitory effect of Dovitinib and Oxaliplatin combination on cell proliferation, the results showed that the combination treatment exhibited higher cytotoxicity in all cell lines | PMC3996163 |
HT-29 | 5.21 μM | 72 hours | To evaluate the inhibitory effect of Dovitinib and Oxaliplatin combination on cell proliferation, the results showed that the combination treatment exhibited higher cytotoxicity in all cell lines | PMC3996163 |
SW-480 | 4.33 μM | 72 hours | To evaluate the inhibitory effect of Dovitinib and Oxaliplatin combination on cell proliferation, the results showed that the combination treatment exhibited higher cytotoxicity in all cell lines | PMC3996163 |
CaCO2 | 3.23 μM | 72 hours | To evaluate the inhibitory effect of Dovitinib and Oxaliplatin combination on cell proliferation, the results showed that the combination treatment exhibited higher cytotoxicity in all cell lines | PMC3996163 |
LS174T | 4.33 μM | 72 hours | To evaluate the inhibitory effect of Dovitinib and Oxaliplatin combination on cell proliferation, the results showed that the combination treatment exhibited higher cytotoxicity in all cell lines | PMC3996163 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
mice | syngeneic tumor model derived from YTN16 cells | oral | 1 μg | Three times a week for 3 weeks | Dovitinib significantly delayed tumor growth in YTN16-derived tumors, increased CD8+ T cell infiltration, and repressed the expression of EMT markers. | PMC10592091 |
nude mice | HT-29 human colorectal cancer xenograft model | oral Dovitinib, intravenous Oxaliplatin | 150 mg/kg D-luciferin or 7.5 mg/kg CycLuc1 | To evaluate the inhibitory effect of Dovitinib and Oxaliplatin combination on tumor growth, the results showed that the combination treatment significantly inhibited tumor growth without showing apparent toxicity | PMC3996163 | |
mice | MDA PCa 118b bone tumor model | oral | 60 mg/kg Dovitinib, 6.7 mg/kg Oxaliplatin | Dovitinib every two days, Oxaliplatin once a week for 3 weeks | Dovitinib significantly reduced tumor volume (assessed by MRI) and improved bone quality in tumor-bearing bones. | PMC4407499 |
Mice | Renal cell carcinoma tumorgraft model | Oral gavage | 40 or 60 mg/kg body weight | daily for 3 weeks | Dovitinib profoundly suppressed the growth of renal cell carcinoma tumorgrafts and was more effective than sunitinib and sirolimus. | PMC3570965 |
Nude mice | Cholangiocarcinoma patient derived xenograft (PDX) mouse model | Oral gavage | 25 mg/kg | single injection, sacrificed after 12 hours | To evaluate the inhibitory effect of Dovitinib on the growth of LIV31 xenograft tumors. The results showed that Dovitinib significantly inhibited tumor growth and was most effective in inhibiting vascular proliferation. | PMC5119950 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT00279773 | Acute Myeloid Leukemia | PHASE1 | TERMINATED | - | The University of Texas, M.D. ... More >>Anderson Cancer Center, Houston, Texas, 77020, United States Less << |
NCT01972750 | First or Second Recurrence of ... More >>Glioblastoma Less << | PHASE1 | UNKNOWN | 2025-11-16 | Department of Neurology and Ce... More >>nter of Integrated Oncology, University Hospital Bonn, Bonn, 53105, Germany Less << |
NCT00303251 | Melanoma | PHASE1|PHASE2 | COMPLETED | - | James Graham Brown Cancer Cent... More >>er, Louisville, Kentucky, 40202, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15232, United States|MD Anderson Cancer, Houston, Texas, 77030, United States Less << |
NCT00790426 | Urothelial Cancer | PHASE2 | COMPLETED | 2025-04-12 | University of California San D... More >>iego - Moores Cancer Center UCSD, La Jolla, California, 92093-0658, United States|USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3, Los Angeles, California, 90053, United States|University Chicago Hospital CTKI258A2201, Chicago, Illinois, 60637, United States|Dana Farber Cancer Institute Dana 1230, Boston, Massachusetts, 02215, United States|Nevada Cancer Institute Nevada Cancer Institute, Las Vegas, Nevada, 89135, United States|Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering (2), New York, New York, 10065, United States|Duke University Medical Center Dept.ofDukeUniversityMedCtr(2), Durham, North Carolina, 27710, United States|The West Clinic, Memphis, Tennessee, 38120, United States|Novartis Investigative Site, Vienna, 1100, Austria|Novartis Investigative Site, Victoria, British Columbia, V8R 6V5, Canada|Novartis Investigative Site, Toronto, Ontario, M5G 2M9, Canada|Novartis Investigative Site, Berlin, 10098, Germany|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Ulm, 89081, Germany|Novartis Investigative Site, Roma, RM, 00152, Italy|Novartis Investigative Site, Sevilla, Andalucia, 41013, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08003, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Barcelona, 08041, Spain|Novartis Investigative Site, Madrid, 28034, Spain|Novartis Investigative Site, Madrid, 28041, Spain|Novartis Investigative Site, Madrid, 28050, Spain|Novartis Investigative Site, Tainan 704, Taiwan ROC, Taiwan|Novartis Investigative Site, Taipei, 10048, Taiwan|Novartis Investigative Site, Leeds, West Yorkshire, LS9 7TF, United Kingdom|Novartis Investigative Site, Southampton, SO16 6YD, United Kingdom Less << |
NCT00669097 | Advanced Solid Malignancies | PHASE1 | COMPLETED | - | Novartis Investigative Site, A... More >>msterdam, Netherlands Less << |
NCT01791387 | Clear Cell Renal Cell Carcinom... More >>a Less << | PHASE2 | UNKNOWN | 2025-06-15 | Auckland Hospital, Auckland, 1... More >>142, New Zealand Less << |
NCT01732107 | Bladder Cancer | PHASE2 | TERMINATED | 2017-03-06 | Indiana University Melvin and ... More >>Bren Simon Cancer Center, Indianapolis, Indiana, 46202, United States|Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21231, United States|Fox Chase Cancer Center Extramural Research Program, Rockledge, Pennsylvania, 19046, United States Less << |
NCT01678105 | Recurrent Adenoid Cystic Carci... More >>noma of the Salivary Glands|Metastatic Adenoid Cystic Carcinoma of the Salivary Glands|Salivary Gland Cancers|ACC Less << | PHASE2 | COMPLETED | 2025-09-15 | Tom Baker Cancer Centre, Calga... More >>ry, Ontario, T2N 4N2, Canada|Juravinski Cancer Centre, Hamilton, Ontario, L8V 5C2, Canada|London Health Sciences Centre, London, Ontario, N6A 4L6, Canada|Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, K1H 8L6, Canada Less << |
NCT01741116 | Hormone Refractory Prostate Ca... More >>ncer Less << | PHASE2 | COMPLETED | 2025-10-16 | Korean Cancer Study Group, Seo... More >>ul, Chongro-ku, 110999, Korea, Republic of|Korea University Anam Hospital, Seoul, Seongbuk-gu, Inchon-ro, 136-705, Korea, Republic of Less << |
NCT01058434 | Relapsed or Refractory Multipl... More >>e Myeloma Less << | PHASE2 | COMPLETED | 2025-02-13 | University of South Alabama / ... More >>Mitchell Cancer Institute Dept. of Mitchell Cancer Inst., Mobile, Alabama, 36688, United States|Central Hematology Oncology Medical Group, Alhambra, California, 91801, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, 93454, United States|St. Jude Heritage Medical Group Virginia Crosson Cancer Center, Yorba Linda, California, 92886, United States|Kootenai Medical Center Kootenai Medical Center, Coeur d'Alene, Idaho, 83814, United States|Hematology and Oncology Specialists Dept of Hem&Onc Specialist - 2, Metairie, Louisiana, 70006, United States|Mayo Clinic - Rochester Rochester, Rochester, Minnesota, 55905, United States|Memorial Sloan Kettering Cancer Center MSKCC, New York, New York, 10021, United States|Duke University Medical Center Dept. of DUMC (4), Durham, North Carolina, 27710, United States|Lancaster Cancer Center, Lancaster, Pennsylvania, 17601, United States|Cancer Centers of the Carolinas Dept. of CC of the Carolinas, Greenville, South Carolina, 29605, United States|University of Tennessee Cancer Institute SC-2, Memphis, Tennessee, 38104, United States|University of Texas Southwestern Medical Center UTSW Medical Center, Dallas, Texas, 75390-8527, United States|University of Wisconsin SC, Madison, Wisconsin, 53792, United States|Medical College of Wisconsin Med College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|Novartis Investigative Site, Adelaide, South Australia, 5000, Australia|Novartis Investigative Site, Melbourne, Victoria, 3002, Australia|Novartis Investigative Site, Prahran, Victoria, 3181, Australia|Novartis Investigative Site, Toronto, Ontario, M5G 2M9, Canada|Novartis Investigative Site, Montreal, Quebec, H3A 1A1, Canada|Novartis Investigative Site, Nantes Cedex 1, 44093, France|Novartis Investigative Site, Bochum, 44892, Germany|Novartis Investigative Site, Heidelberg, 69120, Germany|Novartis Investigative Site, K?ln, 50924, Germany|Novartis Investigative Site, Amsterdam, 1081 HV, Netherlands|Novartis Investigative Site, Rotterdam, 3015 CE, Netherlands|Novartis Investigative Site, Rotterdam, 3075 EA, Netherlands|Novartis Investigative Site, Altunizade, 34662, Turkey|Novartis Investigative Site, Ankara, 06100, Turkey|Novartis Investigative Site, Izmir, 35040, Turkey Less << |
NCT01576380 | Adenocarcinoma, Scirrhous|Lini... More >>tis Plastica|Stomach Neoplasms|Stomach Diseases|Neoplasms by Site|Neoplasms Less << | PHASE2 | COMPLETED | 2025-09-13 | Novartis Investigative Site, N... More >>agoya, Aichi, 464-8681, Japan|Novartis Investigative Site, Kashiwa, Chiba, 277-8577, Japan|Novartis Investigative Site, Matsuyama, Ehime, 791-0280, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, 060-8648, Japan|Novartis Investigative Site, Takatsuki, Osaka, 569-8686, Japan|Novartis Investigative Site, Sunto-gun, Shizuoka, 411-8777, Japan|Novartis Investigative Site, Chuo-ku, Tokyo, 104-0045, Japan|Novartis Investigative Site, Koto, Tokyo, 135-8550, Japan Less << |
NCT01514526 | Adrenocortical Carcinoma | PHASE2 | COMPLETED | 2025-11-16 | Complejo Hospitalario Universi... More >>tario de Santiago, Santiago de Compostela, A Coru?a, 15706, Spain|Hospital Universitario Fundación de Alcorcón, Alcorcón, Madrid, 28922, Spain|Hospital del Mar, Barcelona, 08003, Spain|Hospital Universitario Reina Sofía, Córdoba, 14004, Spain|Hospital Universitario Central de Asturias, Oviedo, 33006, Spain|Complejo Hospitalario de Navarra, Pamplona, 31008, Spain|Fundación Instituto Valenciano de Oncología, Valencia, 46009, Spain Less << |
NCT01471548 | Advanced Solid Tumors | PHASE1 | COMPLETED | 2025-05-12 | Novartis Investigative Site, T... More >>akatsuki, Osaka, 569-8686, Japan|Novartis Investigative Site, Hidaka, Saitama, 350-1241, Japan Less << |
NCT01379534 | Solid Tumors and Advanced Endo... More >>metrial Cancer|Endometrial Cancer|Second-line Treatment|VEGF Less << | PHASE2 | COMPLETED | 2025-03-14 | University of South Alabama / ... More >>Mitchell Cancer Institute Univ South Alabama, Mobile, Alabama, 36688, United States|St. Jude Heritage Medical Group St Jude, Fullerton, California, 92835, United States|USC/Kenneth Norris Comprehensive Cancer Center USC 2, Los Angeles, California, 90033, United States|Cedars Sinai Medical Center TKI258A2211 (SC), Los Angeles, California, 90048, United States|University of California at Los Angeles UCLA 3, Los Angeles, California, 90095, United States|Rocky Mountain Cancer Centers Dept. of Rocky Mountain Cancer, Greenwood Village, Colorado, United States|Florida Hospital Cancer Institute FL Hosp, Orlando, Florida, 32804, United States|Indiana University Health Goshen Center for Cancer IU Simon Cancer, Indianapolis, Indiana, 46202, United States|University of Iowa Hospitals & Clinics SC, Iowa City, Iowa, 52242, United States|Dana Farber Cancer Institute SC, Boston, Massachusetts, 02115, United States|Southeast Nebraska Oncology Cancer Center, Lincoln, Nebraska, 68510, United States|Hope A Woman's Cancer Center, Asheville, North Carolina, 28806, United States|Duke University Medical Center Duke3, Durham, North Carolina, 27710, United States|Community Oncology Research Network, Chattanooga, Tennessee, 37403, United States|The West Clinic SC, Memphis, Tennessee, 38120, United States|Texas Oncology, P.A. Austin, Bedford, Texas, 76022, United States|Texas Oncology, P.A. Tex Onc (3), Bedford, Texas, 76022, United States|Texas Oncology, P.A. SC, Fort Worth, Texas, 76104, United States|South Texas Oncology and Hematology, PA South Tex Onc, San Antonio, Texas, 78258, United States|Virginia Oncology Associates VOA - Lake Wright, *see Various Departments*, Virginia, United States|Cancer Care Northwest SC, Spokane, Washington, 99202, United States|Novartis Investigative Site, Belo Horizonte, MG, 30150-270, Brazil|Novartis Investigative Site, Porto Alegre, RS, 90610-000, Brazil|Novartis Investigative Site, Ribeirao Preto, SP, 14048-900, Brazil|Novartis Investigative Site, Genova, GE, 16132, Italy|Novartis Investigative Site, Monza, MB, 20900, Italy|Novartis Investigative Site, Milano, MI, 20133, Italy|Novartis Investigative Site, Milano, MI, 20141, Italy|Novartis Investigative Site, Pisa, PI, 56126, Italy|Novartis Investigative Site, Roma, RM, 00168, Italy|Novartis Investigative Site, Candiolo, TO, 10060, Italy|Novartis Investigative Site, Seoul, Korea, 135-710, Korea, Republic of|Novartis Investigative Site, Seoul, 738-736, Korea, Republic of|Novartis Investigative Site, Grafton, Auckland, New Zealand|Novartis Investigative Site, Cordoba, Andalucia, 14004, Spain|Novartis Investigative Site, Málaga, Andalucia, 29010, Spain|Novartis Investigative Site, Oviedo, Asturias, 33006, Spain|Novartis Investigative Site, Sabadell, Barcelona, 08208, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Majadahonda, Madrid, 28222, Spain|Novartis Investigative Site, Murcia, 30008, Spain|Novartis Investigative Site, Glasgow, G12 0YN, United Kingdom|Novartis Investigative Site, Leeds, LS9 7TF, United Kingdom|Novartis Investigative Site, London, NW1 2BU, United Kingdom|Novartis Investigative Site, Nottingham, NG5 1PB, United Kingdom Less << |
NCT01443481 | Solid Tumors|Hepatic Impairmen... More >>t Less << | PHASE1 | COMPLETED | 2025-10-14 | University of California at Lo... More >>s Angeles Dept. of UCLA (4), Los Angeles, California, 90095, United States|Duke University Medical Center DUMC, Durham, North Carolina, 27710, United States|Cancer Therapy & Research Center / UT Health Science Center SC, San Antonio, Texas, 78229, United States|Novartis Investigative Site, Gent, 9000, Belgium|Novartis Investigative Site, Frankfurt, 60590, Germany|Novartis Investigative Site, Hannover, 30625, Germany|Novartis Investigative Site, Milano, MI, 20133, Italy|Novartis Investigative Site, Rozzano, MI, 20089, Italy|Novartis Investigative Site, Verona, VR, 37126, Italy|Novartis Investigative Site, Amsterdam, 1066 CX, Netherlands|Novartis Investigative Site, Maastricht, 5800, Netherlands|Novartis Investigative Site, Singapore, 119228, Singapore Less << |
NCT01861197 | Squamous NSCLC | PHASE2 | UNKNOWN | - | Samsung Medical Center, Seoul,... More >> 135-710, Korea, Republic of Less << |
NCT01964144 | Thyroid Cancer | PHASE2 | COMPLETED | 2025-10-14 | Division of Medical Oncology, ... More >>Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, 120-752, Korea, Republic of Less << |
NCT00715182 | Advanced/ Metastatic Renal Cel... More >>l Cancer Less << | PHASE1 | COMPLETED | 2025-07-12 | Novartis Investigative Site, S... More >>an Francisco, California, United States|Novartis Investigative Site, Durham, North Carolina, 27710, United States|Novartis Investigative Site, Seattle, Washington, 98109-1023, United States|Novartis Investigative Site, Bordeaux Cedex, 33075, France|Novartis Investigative Site, Villejuif Cedex, 94805, France|Novartis Investigative Site, Hannover, 30625, Germany|Novartis Investigative Site, München, 81675, Germany|Novartis Investigative Site, Rotterdam, 3075 EA, Netherlands|Novartis Investigative Site, Madrid, 28041, Spain|Novartis Investigative Site, Taipei, Taiwan, ROC, 112, Taiwan|Novartis Investigative Site, Taichung, 40705, Taiwan|Novartis Investigative Site, Taipei, 10002, Taiwan Less << |
NCT01635907 | Advanced Metastatic Paragangli... More >>oma|Advanced Metastatic Pheochromocytoma|Recurrent Paraganglioma|Recurrent Pheochromocytoma|Unresectable Paraganglioma|Unresectable Pheochromocytoma Less << | PHASE2 | COMPLETED | 2016-04-11 | Abramson Cancer Center of the ... More >>University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States Less << |
NCT01262027 | Breast Cancer | PHASE2 | COMPLETED | 2015-11-25 | University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less << |
NCT00958971 | Metastatic Breast Cancer | PHASE2 | COMPLETED | 2025-03-11 | Comprehensive Blood and Cancer... More >> Center Dept CBCC (3), Bakersfield, California, 93309, United States|Tower Cancer Research, Beverly Hills, California, 90211, United States|UCLA/ University of California Los Angeles Div. of Hematology/Oncology, Los Angeles, California, 90095, United States|Cancer Care Associates Medical Group Dept. of CCA, Redondo Beach, California, 90277, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, 93454, United States|Florida Cancer Specialists Dept.of FloridaCancerSpec. (2), Fort Myers, Florida, 33901, United States|Kansas City Cancer Center KCCC (3), Overland Park, Kansas, 66210, United States|Associates in Oncology/Hematology, P.C., Rockville, Maryland, 20850, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, 89052, United States|UNC/ Lineberger Comprehensive Cancer Center Dept. of Linberger Cancer Ctr, Chapel Hill, North Carolina, 27599-7295, United States|Northwest Cancer Specialists Northwest Office (2), Portland, Oregon, 97210, United States|Texas Oncology, P.A. Dept. of Texas Oncology, Bedford, Texas, 76022, United States|Texas Oncology, P.A. Austin, Dallas, Texas, 75246, United States|Texas Oncology, P.A. Presbyterian Hospital, Dallas, Texas, 75246, United States|Texas Oncology, P.A. Texas Oncology - Sammons, Dallas, Texas, 75246, United States|Tyler Cancer Center Dept.ofTylerCancerCtr. (2), Tyler, Texas, 75702, United States|Fairfax Northern Virginia Hematology Oncology Fairfax NVH, Fairfax, Virginia, 22031, United States|Blue Ridge Research Center at Roanoke Neurological Center Blue Ridge Cancer Care, Roanoke, Virginia, 24014, United States|Novartis Investigative Site, Edmonton, Alberta, T6G 1Z2, Canada|Novartis Investigative Site, Montreal, Quebec, H2W 1T8, Canada|Novartis Investigative Site, Helsinki, FIN-00029, Finland|Novartis Investigative Site, Lyon Cedex, 69373, France|Novartis Investigative Site, Saint-Herblain Cédex, 44805, France|Novartis Investigative Site, Toulouse Cedex 3, 31052, France|Novartis Investigative Site, Villejuif Cedex, 94805, France|Novartis Investigative Site, Cuneo, CN, 12100, Italy|Novartis Investigative Site, Cremona, CR, 26100, Italy|Novartis Investigative Site, Parma, PR, 43100, Italy|Novartis Investigative Site, Candiolo, TO, 10060, Italy|Novartis Investigative Site, Napoli, 80131, Italy|Novartis Investigative Site, Negrar, 37024, Italy|Novartis Investigative Site, Barcelona, Catalu?a, 08035, Spain|Novartis Investigative Site, Lleida, Catalu?a, 25198, Spain|Novartis Investigative Site, Madrid, 28041, Spain|Novartis Investigative Site, Taipei, 10048, Taiwan|Novartis Investigative Site, Glasgow, G12 0YN, United Kingdom|Novartis Investigative Site, London, SE1 9RT, United Kingdom|Novartis Investigative Site, London, SW3 6JJ, United Kingdom Less << |
NCT00243763 | Multiple Myeloma | PHASE1 | TERMINATED | - | Mayo Clinic - Arizona, Scottsd... More >>ale, Arizona, 85259, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612, United States|Emory University, Atlanta, Georgia, 30322, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Mayo Clinic - Minnesota, Rochester, Minnesota, 55905, United States Less << |
NCT01266070 | Von Hippel-Lindau Syndrome | PHASE2 | TERMINATED | 2025-12-15 | University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less << |
NCT01421004 | Advanced Solid Tumors|Excludin... More >>g Breast Cancer Less << | PHASE1 | COMPLETED | 2025-07-14 | City of Hope National Medical ... More >>Center SC-2, Duarte, California, 91010-3000, United States|University of California at Los Angeles UCLA LeConte Location, Los Angeles, California, 90095, United States|University of California San Francisco UCSF (SC), San Francisco, California, 94101, United States|Florida Cancer Specialists Sarasota Office, Fort Myers, Florida, 33901, United States|Rush University Medical Center Rush 3, Chicago, Illinois, 60612, United States|Washington University School of Medicine SC, Saint Louis, Missouri, 63110, United States|Montefiore Medical Center Montefiore Medical Center (SC), Bronx, New York, 10467, United States|University of Oklahoma Health Sciences Center OUHSC - SC, Oklahoma City, Oklahoma, 73104, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15232-1305, United States|Sarah Cannon Research Institute Sarah Cannon Research (SC), Nashville, Tennessee, 37203, United States|Sammons Cancer Center - Texas Oncology SC-2, Dallas, Texas, 78246, United States|Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5), San Antonio, Texas, 78229, United States|University of Utah / Huntsman Cancer Institute Huntsman, Salt Lake City, Utah, 84112, United States|University of Wisconsin Univ Wisc, Madison, Wisconsin, 53792, United States Less << |
NCT01676714 | Non-Small Cell Lung Cancer|Col... More >>orectal Cancer Less << | PHASE2 | COMPLETED | 2025-06-16 | University of California Compr... More >>ehensive Cancer Center, Sacramento, California, 95817, United States Less << |
NCT01769547 | Advanced Malignant Pleural Mes... More >>othelioma|MPM Less << | PHASE2 | TERMINATED | 2025-06-15 | Tom Baker Cancer Centre, Calga... More >>ry, Alberta, T2N 4N2, Canada|Juravinski Cancer Centre, Hamilton, Ontario, L8V 5C2, Canada|Ottawa General Hospital Cancer Centre, Ottawa, Ontario, K1H 8L6, Canada|Northeast Cancer Centre, Health Sciences North, Sudbury, Ontario, P3E 5J1, Canada|Princess Margaret Hospital, Toronto, Ontario, M5G 1X6, Canada Less << |
NCT01888965 | Colorectal Cancer|Pancreas Can... More >>cer Less << | PHASE2 | TERMINATED | 2025-10-14 | Georgetown University- Lombard... More >>i Cancer Center, Washington, District of Columbia, 20007, United States Less << |
NCT01155713 | Neoplasm|Cancer|Tumors | PHASE1 | COMPLETED | 2025-11-13 | Scottsdale Healthcare/TGen Cli... More >>nical Research Service TGen Clinical Research Service, Scottsdale, Arizona, 85258, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|Sarah Cannon Research Institute Sarah Cannon Research Instit, Nashville, Tennessee, 37203, United States|University of Utah / Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States Less << |
NCT01719549 | Gastric Cancer | PHASE2 | COMPLETED | 2025-11-16 | Asan Medical Center, Seoul, 13... More >>8-736, Korea, Republic of Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.55mL 0.51mL 0.25mL |
12.74mL 2.55mL 1.27mL |
25.48mL 5.10mL 2.55mL |
|
Dissolving Methods |
in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:
|